EarnoReview
Sisram Medical

Sisram Earnings Analysis: Buyback Plan After 3.6% H1 Growth

Sisram Medical will repurchase up to 1% of its shares. First-half revenue rose 3.6% to $171.4 million as injectables grew 54.2% and Asia-Pacific led gains.

Oct 8, 20262 min read
Modern medical aesthetics clinic treatment room
Modern medical aesthetics clinic treatment room. Image: Medicaldoctor91 via wikimedia (CC BY 4.0)

The news

Sisram Medical Ltd (1696.HK), a medical aesthetics group, said on October 8 that it will repurchase up to 1% of its issued shares in the open market under its existing repurchase mandate. The shares can be cancelled or held as treasury shares, depending on capital management needs. The company said it will implement the plan in a “prudent and disciplined” way and that timing, quantity and price are not assured. Co-CEO and CFO Jiahong Li said the company decided on the plan after assessing its business, financial position and market conditions.

The announcement cited first-half 2026 results: revenue of $171.4 million, up 3.6% from a year earlier. Revenue from international markets excluding North America rose 16.7% to $127.0 million, with Asia-Pacific producing $78.4 million, up 19.1%. Injectables revenue grew 54.2% to $22.2 million, 12.9% of the total.

Our analysis

Our earnings analysis starts with what the growth rates imply. International revenue outside North America makes up about 74% of the total ($127.0 million of $171.4 million). If total revenue rose 3.6% while that segment rose 16.7%, the rest of the business, North America, must have fallen. Working back from the reported figures, North America revenue was roughly $44 million, down on the order of a fifth from about $57 million, though the company does not state this directly.

Injectables are the offset elsewhere: the $22.2 million figure is the company’s “second growth engine” after energy-based devices, and DAXXIFY in mainland China, Profhilo and Hallura are cited as the products behind the push. In devices, the Alma Harmony and Hybrid platforms are described as holding market traction, with new rollouts in Asia-Pacific and localization in China advancing together.

A repurchase of up to 1% is small. It signals management’s view of value more than it changes the balance sheet, and the release does not disclose the cash amount, the time frame or the share price. Sisram, which is majority-owned by Fosun Pharma and has been listed on the Hong Kong Main Board since September 2017, sells to customers in more than 110 countries and regions. The company said it will also assess other shareholder return measures suited to its stage of development.

Asia-Pacific alone, at $78.4 million, is 46% of group revenue and 62% of international revenue outside North America. Injectables at 12.9% of revenue and growing more than 54% show how quickly the mix is shifting, though from a small base. The company cites more than 25 years of expertise in energy-based devices and customers in more than 110 countries and regions, and the buyback does not change that operating picture.

Room for disagreement

The announcement frames the buyback as a sign of confidence, but total growth of 3.6% is modest, and the implied weakness in North America is not discussed. Companies often repurchase shares when they think the market undervalues them, and a cap of 1% leaves room to do very little. The release gives no revenue guidance or margin data to test that confidence.

What to watch

Next are any disclosures of actual repurchases, which will show how much of the 1% is used, and the company’s full-year results for the North America trend. Management says it will integrate R&D, global commercial operations and localized capabilities across hubs in Israel, the United States and China, and will explore partnerships that fit its wellness ecosystem.

Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.